Nutriband Advances Trademark Protection for Abuse-Deterrent Fentanyl Patch

Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has taken a significant step forward in protecting the commercial identity of its lead product candidate. The company announced that it received a Notice of Publication from the U.S. Patent and Trademark Office (USPTO) on September 2, 2024, for trademarks associated with its abuse-deterrent fentanyl transdermal system. This development marks a critical milestone in the path toward potential market entry, as the USPTO will publish the trademarks in the Trademark Official Gazette, triggering a 30-day opposition period. If no objections are raised, the USPTO is expected to issue a Notice of Allowance, moving the trademarks closer to formal registration.

The fentanyl system in question incorporates Nutriband's AVERSA™ abuse-deterrent transdermal technology. This patch is designed to deter abuse and misuse while also reducing the risk of accidental exposure to transdermal fentanyl, a potent opioid. The importance of abuse-deterrent formulations has been underscored by regulatory agencies and public health officials, given the ongoing opioid crisis. Nutriband's technology aims to address these concerns by making it more difficult to extract the active ingredient for illicit use, thereby enhancing the safety profile of a drug class that is both medically essential and prone to diversion.

The company has indicated that the product has potential peak annual U.S. sales of $80 million to $200 million, reflecting the significant market opportunity. This projection is supported by the clinical need for safer opioid delivery systems and the growing acceptance of abuse-deterrent technologies among healthcare providers and payers. Moreover, Nutriband's AVERSA™ technology is protected by patents issued in 46 countries, providing a robust intellectual property moat that could deter competitors and support long-term commercial viability.

The advancement of trademark protection is a strategic move that goes beyond legal formalities. Trademarks are essential for building brand recognition and consumer trust, especially in the pharmaceutical industry where product identity is closely tied to safety and efficacy. By securing trademarks early, Nutriband is laying the groundwork for a cohesive marketing strategy and preparing for a potential product launch. The move also signals to investors that the company is making tangible progress toward commercialization, which could positively influence market sentiment.

For stakeholders, this development is noteworthy because it reduces some of the uncertainties associated with early-stage pharmaceutical companies. The combination of a clear regulatory path for trademarks, a strong patent portfolio, and a product with substantial market potential positions Nutriband favorably within the competitive landscape of transdermal drug delivery. As the company continues to navigate the regulatory and commercial landscape, this milestone serves as a testament to its commitment to addressing critical public health challenges while creating shareholder value.

Further details about the announcement can be found in the full press release at https://ibn.fm/p1wVE. For the latest news and updates about Nutriband, visit the company's newsroom at https://ibn.fm/NTRB.